NY-TRG
11.3.2021 19:26:05 CET | Business Wire | Press release
The Rohatyn Group (“TRG”), a global, US-based asset management firm, today announced that it has completed an investment in the specialized pet accessories company MyFamily Srl (“MyFamily” or the “Company”), establishing a partnership with the Company’s founder, Alessandro Borgese, and existing investors including 035 investimenti S.p.A. TRG’s investment will allow MyFamily to accelerate its product rollout and continue expanding its global distribution channels. Terms of the transaction were not disclosed.
Founded in 2011 in Valenza, Italy, MyFamily is a global producer of engravable pet ID tags and tag engraving machines. The Company’s engraving machines are present in approximately 9,000 retail locations in more than 70 countries worldwide. The Company has recently expanded its pet accessories assortment through a unique range of pet collars, leashes and harnesses, including the technology-enabled Memopet collection, which offers a differentiated smart and interactive experience.
“MyFamily is a highly attractive business that provides a unique product offering in the global pet accessories sector. We believe the Company is well positioned to benefit from accelerated premiumization of pet products and deliver strong growth as the global pet accessories market continues to expand,” said TRG’s Colin Clark, Head of the EMEA Private Markets investment team, and Stepan Karpukhin, Managing Director.
TRG’s Harold Chatelus, who will immediately join the Board of Directors of MyFamily, added, “Alessandro Borgese leads a highly qualified and motivated global management team, whose dedication to product innovation is evident in the quality and design leadership of MyFamily’s product portfolio. TRG will actively support the Company’s expansion strategy with the goal of enhancing scale and solidifying global market leadership.”
Nick Rohatyn, CEO of TRG added, “MyFamily is a high-growth business with international access that fits in perfectly with TRG’s global approach. We believe strongly that the Company has the potential to transform the global pet accessories sector thanks to its innovative and technology-forward strategy. Our investment team will seek to leverage our deep knowledge of the pet care industry and positive experience from current portfolio company Pet Network International to assist Alessandro and his talented team in achieving their growth objectives.”
Alessandro Borgese, founder and CEO of MyFamily, commented, “I am tremendously proud of the growth MyFamily has already achieved, particularly over the last two years, as we have transformed our product portfolio, invested greatly in production quality and automation, and expanded our distribution network following the launch of our US subsidiary. TRG’s investment will accelerate the next phase in MyFamily’s development. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”
About TRG
Founded in 2002, The Rohatyn Group is an emerging markets focused asset management firm headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, San Jose, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005900/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom